Blood Podcast

328 - A novel mouse model of sickle cell SC disease; multiple myeloma induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone; and splicing factor mutations in myelodysplastic syndromes

327 - An AI model for transplant risk in myelofibrosis; preventing priapism in men with sickle cell anemia; hallmarks of T cell exhaustion absent in newly diagnosed MM

326 - Social determinants of health and access to allogeneic hematopoietic cell transplantation, megakaryocyte growth factor receptor-based pretransplant conditioning for ex vivo autologous gene therapy, and novel protein biomarkers for risk stratification in a

325 - Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets

324 - A key role for T-cell TET3 in chronic GVHD; a BTK inhibitor for ITP; co-inhibition of pre-TCR and IL-7R pathways in a T-ALL patient subset

323 - Special Episode: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

322 - How I Treat Series on Geriatric Hematology

321 - Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance

320 - New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE

319 - How I Treat Transfusion Medicine (part 2)

318 - Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymph

317 - How I Treat Transfusion Medicine (part 1)

316 - Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT

315 - Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease

314 - Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature

313 - Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell cardiomyopathy

312 - How I Treat Myeloproliferative Neoplasms

311 - The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCL

310 - Interleukin-1 signaling pathways in myelodysplastic syndromes, the immune checkpoint regulator VISTA as a target in graft-vs-host disease, and epcoritamab plus chemotherapy in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma

309 - Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL

308 - Blood Bonus Episode: What is a Blood group?

307 - Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans, and lack of evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait

306 - Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis

305 - Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALL

304 - Mutations in AMBRA1 aggravate β-thalassemia; targeting MYD88 mutations in lymphomas; air pollution and incident VTE risk

303 - Hypercalcemia in monoclonal gammopathy of undetermined significance, neutrophil gelatinase-associated lipocalin in hemostasis, and CD19-targeted NK- or T-cell therapy combined with anti-CD19 monoclonal antibodies

302 - Review Series on a Quarter Century of TKIs in CML

301 - A “belt and suspenders” approach to PNH; oral pathogens exacerbate chronic GVHD; microbial metabolome changes may adversely impact CAR-T outcomes

300 - Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells

299 - Review Series on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor

298 - Dual TKI targeting in Ph+ ALL; role of liver endothelial ferroportin in iron sensing and homeostasis; severe anemia in pregnant patients with beta-thalassemia minor

297 - First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia

296 - Targeting C3 in autoimmune hemolytic anemias; venetoclax testing to predict AML response; an improved understanding of the structure of FXIII complex

295 - Review Series on Globin Disorders

294 - Brentuximab vedotin, nivolumab, and chemotherapy in classical Hodgkin lymphoma; type 1 interferon signaling in sickle cell disease; and type 1 human leukocyte antigen gene mutations in cutaneous T-cell lymphoma

293 - Iron overload aggravates MDS pathophysiology; long-term outcomes after TPO-RA treatment in ITP; new insights into APL treatment outcomes by age and risk

292 - Dexamethasone dosing in newly diagnosed multiple myeloma, a new experimental model of X-linked sideroblastic anemia, and ciltacabtagene autoleucel in real-world myeloma treatment

291 - Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclax

290 - Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancer

289 - Unravelling follicular lymphoma subtypes; stroke rate trends in sickle cell disease; procoagulant platelet activation promotes venous thrombosis

288 - Clonal hematopoiesis in patients with telomere biology disorders, genomic alterations in extracutaneous juvenile xanthogranulomas, and the BCMA-CD3 bispecific antibody teclistamab in relapsed/refractory multiple myeloma

287 - Targeting mutant calreticulin in MPNs; focusing on bleeding risk in patients with cancer; revisiting diagnostic guidelines for familial HLH

286 - Review Series on T-Cell Lymphoma

285 - Stratifying risk in acute myeloid leukemia, daratumumab plus chemotherapy in relapsed-refractory pediatric leukemias, and a method for creating genetically engineered platelets

284 - Exploring the ecosystem of extramedullary myeloma; role of ruxolitinib for pediatric acute GvHD; “YAP”-ing about YAP1 and thrombopoiesis in ITP

283 - First-line asciminib for chronic myeloid leukemia, a new risk score for clonal cytopenia, and genotyped D-positive blood transfusion in sickle cell anemia

282 - Update on fixed-dose venetoclax-obinutuzumab in previously untreated CLL; dual epi-immunotherapy in cHL; predicting treatment failure in TKI-treated CML

281 - Bone marrow failure related to ERG insufficiency, factor 11 in vascular hyperpermeability, and new criteria for evaluating anemia in myelofibrosis

280 - Platelet glycoprotein receptor VI in abdominal aortic aneurysms, TP53 mutations in 5q-deleted myelodysplastic syndrome, and immunostimulatory cytokine plus CAR T-cell therapy in acute lymphoblastic leukemia

279 - Using NGS to refine risk stratification in T-ALL; a novel gene therapy approach in severe α-thalassemia; molecular taxonomy of MDS